TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the

μ-opioid receptor The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. They are also referred to as μ(''mu'')-opioid peptide (MOP) receptors. The prototypical ...

, selective for activation of the

G-protein G proteins, also known as guanine nucleotide-binding proteins, are a family of proteins that act as molecular switches inside cells, and are involved in transmitting signals from a variety of stimuli outside a cell to its interior. Their ...

signalling pathway over β-arrestin 2 recruitment. It is closely related to

oliceridine Oliceridine, sold under the brand name Olinvyk, is an opioid medication that is used for the treatment of moderate to severe acute pain in adults. It is given by intravenous (IV) injection. The most common side effects include nausea, vomiting ...

and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.

References

Mu-opioid receptor agonists Pyridines Fluoroarenes Spiro compounds Oxygen heterocycles Secondary amines {{analgesic-stub

See also

References